The company will use the new funds to complete product development, conduct clinical trials, gain FDA clearance and prepare for U.S. commercialization of the first product developed from its proprietary 4D cardiac imaging platform, Verafeye.
Get the full story at our sister site, Medical Design & Outsourcing.
OneProjects co-founders Fionn Lahart (left) and Christoph Hennersperger [Photo courtesy of OneProjects]
Irish-German cardiac imaging startup OneProjects today announced $8 million in Series A2 funding and two grants totaling $9 million.The company will use the new funds to complete product development, conduct clinical trials, gain FDA clearance and prepare for U.S. commercialization of the first product developed from its proprietary 4D cardiac imaging platform, Verafeye.
The Series A2 financing was led by imec.xpand, with participation from the European Innovation Council (EIC) Fund and existing investors LSP and Atlantic Bridge Ventures, which led the startup’s Series A1 funding in 2020.
OneProjects said it secured a $6 million grant from the Irish government’s Disruptive Technologies Innovation Fund and a $3 million grant from the EIC Accelerator.
OneProjects aims to improve catheter a…
OneProjects — an Irish-German cardiac imaging startup — announced today that it has raised $12 million (€11 million) in a Series A round.
LSP, based in the Netherlands, investing from its LSP Health Economics Fund 2, and the Atlantic Bridge University Fund (Ireland), led the round, with participation from Enterprise Ireland and a selection of medtech entrepreneurs.
OneProjects, founded in 2017 by CEO Fionn Lahart and CTO Christoph Hennersperger founded OneProjects in 2017 in Dublin Ireland, with significant development activities taking place in Munich, Germany. The company’s Verafeye technology is able to provide 4D data from within the heart, with a goal of increasing the efficacy and safety of atrial fibrillation treatment people around the world.
OneProjects officials plan to use the $12 million to advance product development, carry out clinical trials, and prepare for U.S. commercialization of the system.
“This investment will hel…